Protagonist Therapeutics Inc.‘s $90 million IPO sold 7.5 million shares at $12 each, after the Milpitas, Calif.-based firm had first planned for $70 million by offering 5.84 million shares with insiders buying as much as $40 million. The upsized win bodes well not only for the company’s efforts in oral vs. injectable therapies but also for others hoping to find their places on the public market, though shares (NASDAQ:PTGX) didn’t see much action Thursday, closing at $11.70, down 30 cents.